Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review by Jones, L et al.
a) Title 
Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: 
a systematic review 
 
b) Authors 
Lisa Jones, Centre for Public Health, Liverpool John Moores University; 
Geoff Bates, Centre for Public Health, Liverpool John Moores University; 
Ellie McCoy, Centre for Public Health, Liverpool John Moores University; 
Caryl Beynon, Centre for Public Health, Liverpool John Moores University; 
James McVeigh, Centre for Public Health, Liverpool John Moores University; 
Mark A Bellis, Centre for Public Health, Liverpool John Moores University 
 
c) Name of department and institution 
Centre for Public Health, Research Directorate, Faculty of Health and Applied Social 
Sciences, Liverpool John Moores University, 15-21 Webster Street, Liverpool L3 2ET, UK 
 
d) Diclaimers 
None 
 
e) Correspondence 
Lisa Jones, Centre for Public Health, Research Directorate, Faculty of Health and Applied 
Social Sciences, Liverpool John Moores University, 15-21 Webster Street, Liverpool L3 2ET. 
Email: l.jones1@ljmu.ac.uk. Tel: (0151) 231 4452. Fax: (0151) 231 4552 
 
f) Source of support 
The work was funded by the UK National Institute for Health and Clinical Excellence.  
ABSTRACT  
Background: People who inject drugs are at the greatest risk of acquiring hepatitis C virus 
infection in many high income countries, including those in Europe. Our review examined 
the effectiveness of interventions aimed at increasing hepatitis C virus testing uptake. 
Methods: We undertook a systematic review of controlled studies. Searches of 13 databases 
were supplemented with citation searching, and manual searches of reference lists and 
websites. Studies of interventions that aimed to increase testing uptake among high-risk 
groups were included. Testing uptake was our primary outcome measure of interest and 
secondary outcomes were engagement in follow-up services or treatment. A narrative 
synthesis was undertaken. 
Results: Eight controlled studies were included. Three studies examined interventions in 
primary care; one examined dry blood spot testing as an alternative method of testing, and 
two examined outreach provision. Two further studies examined interventions to improve 
hepatitis C management. Targeted case finding in primary care, support and training for 
primary care practitioners, offering alternative testing, and provision of outreach testing all 
increased uptake of testing; however intervention effects were variable. 
Conclusions: Evidence from the available studies suggests that increases in testing uptake can 
be achieved. Careful attention needs to be paid to the resource implications associated with 
implementation of interventions in primary care settings and also of the potential for 
interventions to improve outcomes once a positive diagnosis has been made. Further research 
on the cost-effectiveness of the intervention approaches examined in this review is required. 
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INTRODUCTION 
Hepatitis C virus infection represents a major public health problem worldwide.1 Within the 
World Health Organization (WHO) European region, approximately nine million people are 
chronically infected with the hepatitis C virus (HCV),2 and as in other high-income regions, 
people who inject drugs (PWIDs) are at greatest risk of acquiring infection.3 Despite the 
burden associated with HCV, it is still a neglected disease in many countries in Europe.4 A 
Call to Action for the EU and Member States on hepatitis B and C was launched in 2011 with 
the goal of making viral hepatitis a public health priority.5 Within the last decade, calls for 
action have also been launched in individual European countries, but with differing levels of 
success.6 So far, government-led, sustainable improvements in screening of high-risk groups 
have only been made in France and Scotland.4 Whilst effective antiviral therapies for HCV 
have become available within the last decade, coordinated and robust responses to the 
broader public health issues associated with tackling transmission of the virus have lagged 
behind.5 7 In many European countries, problems persist in the effective diagnosis and referral 
of patients and although knowledge of HCV status is critical for preventing transmission and 
for initiating early treatment and care, the European Liver Patients Association found that 
many people are unaware of their HCV status at the time of infection.7 Furthermore, although 
an increasing number of studies have shown that PWIDs who have acquired HCV can be 
successfully treated,9 10 very few go on to receive HCV treatment.11-13  
European countries are therefore facing a major challenge to improve identification of 
individuals at high-risk of HCV. In order to inform policy and practice responses, we carried 
out a systematic review of the effectiveness of interventions aimed at increasing uptake of 
case finding and testing among high-risk groups and health professionals involved in the 
promotion or provision of HCV testing. 
METHODS 
This study was conducted as part of a series of extensive systematic reviews to inform policy 
recommendations on ways of offering hepatitis B (HBV) and HCV testing in England by the 
National Institute for Health and Clinical Excellence (NICE). We conducted our systematic 
review in accordance with NICE methods14 and followed the PRISMA statement for 
transparent reporting. Accordingly, a protocol documenting the background, objectives and 
methods was prepared in advance of the review (available on request from the authors).  
Search strategy 
A comprehensive search approach was taken. Searches were conducted in 13 databases (see 
Figure 1), with additionally, citation searching, searches of the reference lists of retrieved 
studies and searches of relevant websites. Searches were limited to articles published since 
1990 and were conducted in July 2011. 
Search strategies were developed for each database using a combination of free text and 
thesaurus terms. As this work was conducted as part of a broader review on HBV and HCV 
testing search terms relating to both types of hepatitis (e.g. by exploding the MeSH term 
‘Hepatitis C’) and testing (e.g. case find*, test*) were combined with relevant terms for 
intervention, outcome and evaluation, professional role, setting, population or professional 
education. 
Study selection and eligibility criteria 
Titles and abstracts were initially screened by one reviewer from a team of three (LJ, EMC 
and GB) and the lead reviewer (LJ) independently second screened 30% of the references. 
Titles and abstracts of any potentially relevant articles identified at this stage were then 
rescreened by two reviewers from the same team. Relevant articles identified following this 
stage were retrieved as full text publications and screened by two reviewers independently 
(again from the same team) to determine whether the study met the inclusion criteria. While 
studies of any design were eligible for inclusion in the broader review for this paper we 
focused on the findings from controlled studies, further limiting inclusion to randomised 
controlled trials (RCTs), controlled non-randomised studies (NRCTs), and controlled before 
and after (CBA) studies that compared an intervention against no intervention or another type 
of intervention (e.g. continuation of current testing practice). Fourteen uncontrolled studies 
(e.g. case series) were identified through our searches, but were excluded from the main 
analyses presented here. We included studies of any type of intervention that aimed to raise 
awareness of, or engagement in, HCV testing among high-risk groups. HCV infection is 
highly prevalent among PWID and while they are the population primarily targeted for HCV 
testing studies of interventions that targeted non-PWID high-risk populations were also 
included. Studies that focused on changing behaviours in relation to injection or sharing 
practices among PWIDs, but without reference to HCV testing, were not eligible for 
inclusion. Change in testing uptake was the primary outcome measure of interest. We defined 
this broadly, including changes in the number of participants: (i) requesting or accepting a 
test; (ii) undergoing testing; (iii) receiving a positive test; or (iv) referred to treatment. 
Changes in the number of participants testing positive who engaged in follow-up services 
and/or treatment were examined as secondary outcomes. 
Data extraction and quality assessment 
Data relating to study design and quality were extracted by one reviewer from a team of two 
(EMC and GB) and independently checked for accuracy by a second reviewer (LJ). 
Disagreements were resolved through consensus and when necessary a third reviewer 
consulted. Data were extracted from the included studies on: author; publication year; 
country; research funding source; study objectives; study design/characteristics (e.g. 
eligibility criteria); participants (e.g. age and gender); intervention; analysis/outcomes 
measured; and results. Two reviewers independently undertook quality assessment using 
NICE checklist criteria;14 a revised version of the Graphical Appraisal Tool for 
Epidemiological studies.15 
Data analysis and synthesis 
We summarised the outcomes of data extraction and quality assessment in tables and as a 
narrative summary. Studies were grouped according to the type of intervention examined and 
the possible effects of study quality on the effectiveness data and review findings discussed. 
Where possible, intervention effectiveness was investigated by examining the difference 
between pre- and post-intervention changes in testing uptake. Otherwise, effectiveness was 
investigated by examining the difference in post-intervention testing uptake between 
intervention and control groups. To provide a comparison of effect sizes across the 
interventions examined we used Wilson’s Effect Size Calculator16 to calculate Cohen’s d and 
corresponding 95% confidence intervals using the logit method based on the proportion of 
intervention and control participants completing a HCV test. We chose not to pool effect 
sizes due to heterogeneity across the studies in the populations, settings and interventions 
examined. We developed a logic model to guide the narrative synthesis and to explore 
potential relationships between the interventions identified and outcomes. The logic model 
(Figure 2) depicts the links between the types of interventions identified, the settings in which 
they are delivered and the intended change in outcomes. 
RESULTS 
We retrieved 12,656 references and assessed 299 full text articles (Figure 1). Eight controlled 
studies, from the UK,17-19 France,20 21 the Netherlands,22 Ireland,23 and the USA24 met our 
inclusion criteria (Table 1). This included five RCT and three NRCTs. Three studies 
examined interventions designed to enhance case finding and testing in primary care.17 18 20 
One study examined interventions designed to increase access to testing services based on 
offering alternative methods of testing,19 and two studies21 24 examined HCV testing in 
outreach settings. Two studies22 23 examined interventions designed to improve management 
of HCV among health professionals. 
Raising awareness and encouraging use of testing services 
A French study20 examined the impact of assistance with HCV screening for general 
practitioners (GPs). GPs receiving the intervention were assisted with the screening 
programme through the provision of information (posters/leaflets) in surgery waiting rooms. 
Two UK studies17 18 evaluated opportunistic case finding in general practices in areas of high 
injecting drug use and HCV prevalence. Both interventions targeted individuals aged 30-54 
years, and the intervention examined by Cullen and colleagues18 was also limited to 
individuals with indicators of past injecting drug use. All patients meeting the inclusion 
criteria and attending for non-urgent appointments were offered screening and given an 
information leaflet; individuals accepting the offer could immediately attend, or return for, an 
appointment. 
In the French study,20 provision of patient information was associated with a significantly 
higher number of post-intervention patient requests for testing compared with GPs receiving 
training only. HCV tests were undertaken at the request of the patient in 35.7% of cases in 
intervention practices compared to 19.5% of cases in control practices (p<0.001 for 
comparison).20 However, although this demonstrated the value of providing information to 
patients, there was no significant impact on the overall number of tests requested per GP in 
intervention and control practices (net difference in post-intervention tests requested per GP = 
-0.5 tests). Two UK studies17 18 found that targeted case finding in primary care had a positive 
impact on the number of patients offered and accepting a test. In one study,17 the proportion 
of eligible patients tested increased from pre- to post-intervention by 9.9% in the intervention 
practice compared to a decrease of 0.1% in the control practice. Intervention was associated 
with low diagnostic yield, with 12.8% of intervention patients (n=15/117) testing HCV 
positive. No control patients were tested during the intervention period.17 Among intervention 
practices that implemented a case finding intervention specifically targeting former PWIDs, 
0.8% of the practice population aged 30-54 years were tested for HCV compared to 0.3% in 
control practices.18 The proportion of patients who were tested and received a positive 
(antibody) test was 70.5% in intervention practices compared to 22.2% in control practices. 
Opportunistic case finding in primary care was found to have had a mixed impact on the 
number of patients starting HCV treatment following referral.17 18 Although referral rates 
were relatively high (Table 2), both studies found a high rate of failure to attend, and dropout 
from, follow-up services (around 70%17 and 50%18 in the two studies, respectively). Neither 
study examined reasons for non-attendance or dropout. 
Increasing access to testing services 
One cluster RCT19 examined the impact of offering dried blood spot (DBS) testing as an 
alternative to venepuncture in substance misuse services, drug clinics and prisons. Hickman 
and colleagues19 randomised services to offer DBS testing undertaken by drugs workers or 
testing as usual. The internal validity of the study was potentially affected by inconsistency in 
exposure to the intervention and the authors questioned whether the study was adequately 
powered to detect an intervention effect. Two RCTs, based on individual21 and cluster24 
randomisation respectively, examined whether provision of testing in non-specialist 
community services increased access to testing and follow-up services. One study examined 
an intervention targeting refugees and asylum seekers housed in shelters24 and the other, 
patients at mental health treatment sites with co-occurring mental health and substance abuse 
disorders.21 
Increases in HCV testing uptake were found in drug services and prisons offering DBS 
testing alongside other means of testing, compared to services offering venepuncture only.19 
An overall significant positive effect of introducing DBS testing was found when all 
intervention sites were compared to control sites (weighted absolute increase in testing uptake 
= 10.8%; 95% CI: 0.1%–21%; p=0.05). However, the size of the treatment effect varied 
considerably across paired intervention and control sites, with differences in the proportion of 
patients tested ranging from -0.5% to 69.4%. Whilst reasons for variation in the treatment 
effect were not clear, the authors noted that the two sites with the highest difference in 
treatment effect attributed the increase “simply to an interest in HCV”.19 
Integration of testing services within non-specialist community settings also had a positive 
effect on testing uptake. Participation in the STIRR programme21 within mental health 
treatment sites was associated with significantly higher acceptance of HCV testing among 
patients compared to control sites, in which patients were directed to off-site services (STIRR, 
86.4% vs. control, 14.5%; p<0.001). Outreach testing,24 also improved testing acceptance and 
uptake; with testing completion significantly higher among participants who received either 
intervention approach compared to control (on-site testing vs. control group: odds ratio [OR] 
98.5, 95% CI 51.9–200.8; testing by referral vs. control group: OR 49.8, 95% CI 26.1–102.1; 
provision of on-site testing vs. testing by referral OR 2.0, 95% CI: 1.3–2.9). However, despite 
the positive intervention effects, 30% of participants accepting a test did not complete one, 
with the authors finding that participants changed their minds because of a fear of having 
blood taken. 
Aimed at professionals 
Two studies22 23 examined interventions designed to improve health professionals’ 
management of HCV testing and treatment. Both studies22 23 evaluated complex interventions, 
comprising educational materials and education sessions for GPs in support of a public 
awareness campaign22 in a NRCT, and a nurse-led 6-month intervention to support the 
implementation of guidelines on the management of HCV in primary care in an cluster 
RCT.23 
The intervention supporting implementation of clinical guidelines improved HCV screening 
rates amongst patients on methadone maintenance treatment. In intervention practices, 49.0% 
of patients were screened compared to 27.2% of the control group (adjusted OR: 3.76, 95% 
CI 1.3–11.3).23 Educational materials and education sessions for primary care practices also 
had positive intervention effects on testing uptake.22 The post-intervention testing uptake in 
the intervention region was 2.2 times (95% CI 1.5–3.3) as high as in the control region and 
the intervention was associated with a 2.6% (95% CI -0.7%–5.8%) increase in the number of 
positive tests. However, the clinical significance of these comparisons was not clear and the 
intervention was associated with a low diagnostic yield. 
Effects on referral and treatment outcomes were explored in one study.23 The intervention 
supporting clinical guideline implementation was associated with an increase in referrals for 
assessment at a hepatology clinic. However, after correction for clustering the corresponding 
adjusted OR was no longer statistically significant (OR 3.15; 95% CI 0.9–10.7). The authors 
suggest that this finding may be explained by the short duration of the study or by this 
outcome being subject to a clustering effect. 
Comparison of effect sizes across studies 
Data was available to calculate effect sizes for six of the eight studies included in the review 
(Table 2). The effect sizes (Cohen’s d) calculated ranged from 0.54 to 2.52. The largest effect 
sizes were associated with interventions based on the delivery of services in non-specialist 
community settings.21 24 
DISCUSSION 
Main findings 
We conducted a systematic review of all available controlled studies of interventions aimed 
at increasing uptake of voluntary HCV testing among high-risk groups. Although we found 
relatively few controlled studies, a range of approaches were examined, including 
interventions designed to enhance case finding and testing uptake in primary care,17 18 20 offer 
alternative methods of testing,19 deliver services in non-specialist community settings21 24 and 
improve HCV management among health professionals.22 23 
Based on current evidence it appears that targeted case finding, support and training for 
primary care practitioners, offering DBS testing, and the provision of outreach testing may 
increase HCV testing uptake among high-risk groups. However, the effects of these 
interventions on testing uptake were variable, as shown by the comparison of effect sizes. It 
is also important to consider the limitations of the interventions examined for improving 
outcomes once a positive HCV diagnosis has been made. Although this review focused 
primarily on testing uptake, as the primary aim of testing should be to identify positive 
individuals and to offer them appropriate management and treatment, it is important to note 
that high-risk groups, and in particular PWIDs, may encounter further barriers to care after 
diagnosis. These include problems with accessing referral and counselling,25 poor attendance 
at follow-up services,26 27 being denied opportunities to access treatment and receiving a lack 
of information on treatment options.26 28 Further research on how to increase engagement in 
HCV care and treatment following a positive diagnosis is needed to ensure that such barriers 
are reduced. Furthermore, there needs to be a greater awareness of the potential for treatment 
to substantially reduce the prevalence of HCV infection, particularly among PWIDs.29 
Primary care services are an important setting for identification of HCV infection and five of 
the included studies examined intervention approaches in this setting.17 18 20 22 23 Targeted case 
finding increased testing uptake and case yield in general practices in areas of high HCV 
prevalence16 17 but in other studies increases in diagnostic yield were low.22 Although a cost-
utility study30 31 found it was likely that case finding for HCV in primary care among one of 
the key high-risk groups, in this case former users of injecting drugs, would be considered 
cost-effective, there were substantial uncertainties in the estimates used. The authors of two 
UK studies17 18 noted that GPs had found the process of offering a test and obtaining a sample 
time consuming, and that sometimes multiple appointments were required to complete the 
testing process. The time and resource implications associated with primary care-based 
interventions therefore need to be considered and further research on the cost-effectiveness of 
this and the other intervention approaches examined in this review is required.  
Uncontrolled studies 
We identified six uncontrolled studies through our searches that examined intervention 
approaches of relevance to our review. Although the results of uncontrolled studies should be 
treated with great caution, they provide some further context to the intervention approaches 
examined in controlled studies. The potential to improve testing uptake by broadening access 
to HCV services within community settings was shown in four studies.32-35 Two studies of 
particular relevance found that targeting current drug users through multidisciplinary or 
shared care approaches to HCV testing and treatment was associated with good uptake of 
follow-up services, and treatment outcomes considered comparable to those seen in non-drug 
using populations.34 35 Drawing on qualitative research undertaken with PWIDs, convenient 
and opportunistic testing and location of HCV services, including treatment, in one setting 
appears to be an important facilitator of testing and management.27 36 For interventions aimed 
at improving professional practices, a study of a French national awareness campaign 
demonstrated that without support, offers of testing by primary care professionals may 
increase but not within the desired high-risk groups.37 Another study38 found that the number 
of clients tested for HCV was nearly six times greater after DBS testing was introduced 
compared to the number tested off-site by venepuncture in the previous year. The authors 
noted that the increase in uptake may have been attributable to the increased availability of 
on-site testing rather than solely to the introduction of an alternative method of testing. 
Scope and limitations of the review and published literature 
The scope of the review was broad and covered a range of intervention approaches and 
settings. The search strategy developed was comprehensive but resulted in the retrieval of a 
large number of irrelevant references indicating high sensitivity, but low precision. It is 
possible that some relevant studies were missed, but including multiple strategies minimised 
this likelihood. Although limiting inclusion to controlled studies excluded a number of 
studies of relevant approaches, including uncontrolled studies in the main analyses would 
have introduced the potential for bias in determining effectiveness and risked overestimation 
of intervention effects. Alongside this consideration, there were uncertainties as to whether 
potential sources of bias had been minimised in the included controlled studies. Limitations 
were identified using the checklist quality criteria; in three RCTs,20 21 24 there were 
reservations about whether selection bias had been minimised and across all studies follow-
up times were generally six months or less and consequently not long enough to fully assess 
the long-term harms or benefits of intervention. The internal validity of one RCT was also 
potentially affected by whether the study was adequately powered to detect an intervention 
effect.19 In addition, effect size estimates were not reported or calculable for two studies 
based on non-random allocation.17 18 A further limitation of the published literature was the 
differences in the types of outcomes reported across the included studies. Whilst all studies 
reported a measure of the number of participants completing testing, only three studies 
reported the proportion of participants testing HCV positive (Table 1).  
Conclusions 
In conclusion, despite a number of methodological limitations, evidence from available 
studies of interventions aimed at increasing uptake of HCV testing with high-risk groups 
suggests that increases can be achieved. However, careful attention should be paid to the 
resource implications associated with implementation of the interventions examined in this 
review and of the potential for interventions to improve outcomes once a positive HCV 
diagnosis has been made. 
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KEYPOINTS 
• Existing evidence on the effectiveness of interventions aimed at increasing engagement in 
testing among groups at risk of HCV infection, and health professionals involved in the 
promotion or provision of testing is limited. 
• Eight controlled studies were identified that examined a range of approaches aimed at 
increasing engagement in HCV testing among high-risk populations. 
• Our review indicates that targeted case finding in primary care, support and training for 
primary care practitioners, offering dried blood spot testing, and the provision of outreach 
testing may increase uptake of HCV testing among high-risk groups; however the effects 
of these interventions is variable. 
• The interventions examined had a limited impact of on referral and treatment outcomes 
following a positive HCV diagnosis. 
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Table 1. Summary of study characteristics 
Study Study 
design 
Target population 
(Number of 
patients in 
intervention/ 
control) 
Setting,  
(Number in 
intervention/ 
control) 
Intervention Interventio
n phase 
Outcomes 
Requesting or accepting 
a test 
Completing testing HCV positive (antibody) 
test 
I C  I C  I C  
Anderson 
2009 
NRCT Practice population 
aged 30-54 years 
(n=1,165/914) 
General practices 
(n=1/1) 
Opportunistic age 
criterion based 
screening 
Before  ··· ··· ··· 0.06% 0.04% 10.0
% 
··· ···  
During  ··· ··· ··· 10.0%  0.0% 12.8% 0.0% 12.8% 
Cullen 2006 RCT Health 
professionals 
(n=104/92) 
General practices 
(n=13/12) 
Implementation of 
clinical guidelines 
Before  ··· ··· ··· 33.7% 26.1% 14.2
% 
··· ··· ··· 
During  ··· ··· ··· 49.0% 27.2%   
Cullen 2011 NRCT Former PWIDs 
(n=13,037a/14,189) 
General practices 
(n=8/8) 
Targeted, age based 
screening 
During  0.9% ··· ··· 0.8% 0.3% 0.5% 70.5% 22.2% 48.3% 
Helsper 
2010 
NRCT Health 
professionals (NR) 
Primary care 
services 
(n=110/109) 
Support programme Before ··· ··· ··· 57b 86 b ··· 0.0% 1.7% 2.6% 
During  ··· ··· ··· 172 b 118 b 1.7% 0.8% 
Hickman RCT PWIDs Drug treatment DBS testing Before  ··· ··· ··· 8.4% 7.7% 14.5 ··· ··· ··· 
Study Study 
design 
Target population 
(Number of 
patients in 
intervention/ 
 
Setting,  
(Number in 
intervention/ 
 
Intervention Interventio
n phase 
Outcomes 
Requesting or accepting 
a test 
Completing testing HCV positive (antibody) 
test 
2008 (n=6,650/5,800) clinics and prisons 
(n=14/14) 
During  ··· ··· ··· 20.6% 5.4% %   
Rosenberg 
2010 
RCT Co-occurring 
mental 
health/substance 
use disorders 
(n=118/118) 
Mental health 
programme (NR) 
Direct provision of 
BBV services 
Before  ··· ··· ··· 18.6% 22.9% 76.2
% 
··· ··· ··· 
During  ··· ··· ··· 86.4% 14.5%   
Roudot-
Thorval 
2000 
RCT GPs General practices 
(n=94/90) 
Posters and leaflets 
in waiting room 
During 35.7% 19.5% 7.0% 3.1c 3.6 c     
Sahajian 
2011 
RCT Refugees and 
asylum seekers (n= 
A 222; B 243/811) 
Homeless shelters 
(n=A 6; B 6/6) 
A Testing by 
referral 
During 72.5% NR NR 42.8% 1.5% 41.3
% 
NR NR ··· 
B On-site testing During 77.4% NR NR 59.7% 1.5% 58.2
% 
   
BBV, blood borne virus; C, control group; DBS, dry blood spot; GP, general practitioner; I, intervention group; NRCT, non-randomised controlled trial; PWID, people who inject drugs. RCT, 
Study Study 
design 
Target population 
(Number of 
patients in 
intervention/ 
 
Setting,  
(Number in 
intervention/ 
 
Intervention Interventio
n phase 
Outcomes 
Requesting or accepting 
a test 
Completing testing HCV positive (antibody) 
test 
randomised controlled trial; NR, not reported; ···, outcome not reported; aBased on practice population aged 30-54 years (n=485 with a history of injecting drug use); b Number of tests. c 
Number of tests per GP 
 
Table 2. Comparison of effect sizes across the included studies 
Study Sample size Proportion 
completing test 
Pre and post 
difference % 
Effect size (95% CI) 
I C I % C % Ipost-
Ipre 
Cpost-
Cpre 
Anderson 2009 1,165 914 10.0 0.0 9.9 -0.1 Not calculable 
Cullen 2006 104 92 49.0 27.2 15.4 1.1 1.54 (0.42, 2.66) 
Cullen 2011 13,037 14189 0.8 0.3 0.8 0.3 0.54 (0.35, 0.74) 
Helsper 2010 NR NR ··· ···   Not calculable 
Hickman 2008 6,650 5800 20.6 5.4 12.2 -2.3 0.84 (0.76, 0.91) a 
Rosenberg 2010 81 69 86.4 14.5 67.8 -8.4 2.00 (1.49, 2.51) a 
Roudot-Thorval 2000 NR NR ··· ···   Not calculable 
Sahajian 2011; Testing 
by referral 
222 811 42.8 1.5 42.8 1.5 2.15 (1.80, 2.49) 
Sahajian 2011; On-site 
testing 
243 811 59.7 1.5 59.7 1.5 2.52 (2.18, 2.87) 
NR, not reported; ···, outcome not reported; a Calculated based on post intervention difference. 
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273 references identified as potentially 
relevant based on titles and abstracts
299 references identified for 
further title and abstract screening
26 references identified 
through other sources
131 full text 
articles 
screened
50 included 
studies
8 studies not available
73 excluded:
32 excluded on study design
17 excluded on intervention type
12 cost-effectiveness studies of screening 
in particular populations
7 did not examine effectiveness
4 excluded on population
1 duplicate reference
168 excluded:
73 did not examine effectiveness
53 excluded on intervention type
32 literature reviews, descriptive articles, 
guidelines, editorials or commentaries
4 duplicate references
2 foreign language articles
2 studies of people infected with HIV
1 cost study
1 study did not report relevant outcomes
8 controlled studies 
examined interventions 
targeting the uptake of 
hepatitis C testing
28 excluded from this review:
9 studies examined interventions targeting 
the uptake of hepatitis B testing 
10 studies did not report measures of 
testing uptake
9 publications of 5 cost-effectiveness 
studies
14 uncontrolled studies
12,656 references retrieved 
from 13 electronic sources*
*ASSIA, the British Nursing Index, CINAHL, The Cochrane Library, EMBASE, the 
EPPI Centre databases, the British Library Electronic Theses Online Service, King’s 
Fund catalogue, MEDLINE, PsycINFO, Social Care Online, Social Science Citation 
Index and Sociological Abstracts
 
Figure 2. Flow of information through the different phases of the systematic review  
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Figure 2. Logic model to explore relationships between interventions and intended outcomes 
 
